Maybe you should read the annual report - The Company was...

Maybe you should read the annual report -

The Company was established with the goal to supply medical grade cannabis based therapeutics
products to the rapidly growing international market, with regulated medical cannabis legislation. The
Company’s core focus was initially to research, develop and commercialise cannabis products for
the administration of Medical Grade Cannabis (MGC) as well as to seek further acquisitive opportunities
within the global cannabis market in line with the Company’s overall goal to become a vertically
integrated enterprise that is able to service all parts of the medical cannabis industry.

MMJ is the head of the octopus, I don't think it intends to eat itself to make one arm stronger. If you'd been here longer, you might recognise the words "farm to pharma" and "vertically integrated". MMJs intent all along has been to facilitate a group of complementary entities  across the whole supply chain, which is why Phytotech aquired MMJ Biomed, got a licence, RTO'd Harvest One, and agreed to let PanCann into the squad for stumping up construction. MMJ finds and unites components.

Btw, I though "sublicence" implied that you were licencing someone else to use a licence you got of a primary entity. So if Satipharm is sublicencing to Phytotech, who is Satipharm licencing from?

GelPell AG - http://www.gelpell.com/

Satipharm hold a licence for the manufacturing process, but Phytotech hold the IP rights to PTL101 and PTL201, the precription medicine.